First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

Citation
Marx N, McGuire DK, Johansen O, et al. Eur Heart J 2019;40(Suppl 1):P6272.